首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 非專利藥 > 美國學名藥市場今後的展望
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

美國學名藥市場今後的展望

U.S. Generic Pharmaceuticals Outlook

出版商 Frost & Sullivan
出版日期 2007年04月 商品編碼 51697
內容資訊 英文 66 Pages
價格
US $ 6000 Web Access (Regional License)
US $ 6500 Hard Copy & Web Access (Regional License)


美國學名藥市場今後的展望 是由出版商Frost & Sullivan在2007年04月所出版的。 這份英文市場調查報告書包含66 Pages 價格從美金6000起跳。

目錄

Abstract

This Frost & Sullivan research service titled U.S. Generic Pharmaceuticals Market Outlook provides a detailed analysis of this market, including competitive structure, market and revenue forecasts, and market share analysis. It also examines the major industry challenges and identifies the most promising opportunities for future market growth.

This research service is available through our Pharmaceuticals and Biotechnology Growth Partnership Service program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils.

Table of Contents

1 EXECUTIVE SUMMARY

  • Executive Summary
    • Executive Summary

2 U.S. GENERIC PHARMACEUTICALS MARKET

  • Market Overview
    • Introduction
    • Scope and Segmentation
    • Research Methodology
  • Market Dynamics
    • Market Engineering Measurements
    • Market Trends
    • Financial Snapshot
  • Market Forecasts
    • Prescription Forecasts
    • Revenue Forecasts
  • Competitive Landscape
    • Competitive Structure
    • Pipeline Analysis
    • Market Share Analysis
  • Challenges and Opportunities
    • Industry Challenges
    • Opportunities

3 DECISION SUPPORT DATABASES

  • Demographic Indicator
    • Total Population
  • Market Indicators
    • Government Healthcare Expenditure
    • Private Healthcare Expenditure
    • Pharmaceutical R&D Expenditure
    • Percent Pharmaceutical R&D Expenditure
    • Number of Hospitals
Back to Top